85 related articles for article (PubMed ID: 17611105)
1. Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
Liu ZY; Wang B; Zhao LX; Li YH; Shao HY; Yi H; You XF; Li ZR
Bioorg Med Chem Lett; 2007 Sep; 17(17):4851-4. PubMed ID: 17611105
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
Honda T; Kubo S; Masuda T; Arai M; Kobayashi Y; Yamashita M
Bioorg Med Chem Lett; 2009 Jun; 19(11):2938-40. PubMed ID: 19414262
[TBL] [Abstract][Full Text] [Related]
3. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.
Kawai N; Ikematsu H; Iwaki N; Maeda T; Kanazawa H; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Nagai T; Horii S; Hirotsu N; Kashiwagi S
J Infect; 2008 Jan; 56(1):51-7. PubMed ID: 17936910
[TBL] [Abstract][Full Text] [Related]
6. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.
Medeiros R; Rameix-Welti MA; Lorin V; Ribaud P; Manuguerra JC; Socie G; Scieux C; Naffakh N; van der Werf S
Antivir Ther; 2007; 12(4):571-6. PubMed ID: 17668567
[TBL] [Abstract][Full Text] [Related]
7. Zanamivir treatment is equally effective for both influenza A and influenza B.
Kawai N; Ikematsu H; Iwaki N; Tanaka O; Yamanishi Y; Hirotsu N; Kashiwagi S
Clin Infect Dis; 2007 Jun; 44(12):1666. PubMed ID: 17516418
[No Abstract] [Full Text] [Related]
8. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Magano J
Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
[No Abstract] [Full Text] [Related]
9. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
[TBL] [Abstract][Full Text] [Related]
11. Total Synthesis of Anti-Influenza Agents Zanamivir and Zanaphosphor via Asymmetric Aza-Henry Reaction.
Lin LZ; Fang JM
Org Lett; 2016 Sep; 18(17):4400-3. PubMed ID: 27541804
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
Haldar J; Chen J; Tumpey TM; Gubareva LV; Klibanov AM
Biotechnol Lett; 2008 Mar; 30(3):475-9. PubMed ID: 17972018
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
[TBL] [Abstract][Full Text] [Related]
14. Topology-Matching Design of an Influenza-Neutralizing Spiky Nanoparticle-Based Inhibitor with a Dual Mode of Action.
Nie C; Parshad B; Bhatia S; Cheng C; Stadtmüller M; Oehrl A; Kerkhoff Y; Wolff T; Haag R
Angew Chem Int Ed Engl; 2020 Sep; 59(36):15532-15536. PubMed ID: 32421225
[TBL] [Abstract][Full Text] [Related]
15. Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958.
Tian J; Zhong J; Li Y; Ma D
Angew Chem Int Ed Engl; 2014 Dec; 53(50):13885-8. PubMed ID: 25314609
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques.
Stittelaar KJ; Tisdale M; van Amerongen G; van Lavieren RF; Pistoor F; Simon J; Osterhaus AD
Antiviral Res; 2008 Nov; 80(2):225-8. PubMed ID: 18647621
[TBL] [Abstract][Full Text] [Related]
17. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Bauer K; Richter M; Wutzler P; Schmidtke M
Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
[TBL] [Abstract][Full Text] [Related]
18. Zanamivir: new indication. Influenza: in children as in adults, symptom relief or vaccination.
Prescrire Int; 2008 Aug; 17(96):141. PubMed ID: 19480096
[TBL] [Abstract][Full Text] [Related]
19. Antivirals and influenza: frequency of resistance.
Monto AS
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
[TBL] [Abstract][Full Text] [Related]
20. Human cell lines used in a micro neutralization test for measuring influenza-neutralizing antibodies.
Mittelholzer CM; Brokstad KA; Pauksens K; Jonsson R; Brytting M; Linde A
Scand J Immunol; 2006 Apr; 63(4):257-63. PubMed ID: 16623925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
